Compared with NASH Recip mice, the (NASH + DSF) Recip mice showed significantly reduced levels of serum ALT, serum AST, hepatic TG, liver index (%), hepatic steatosis, lobular inflammation and hepatic fibrosis (Supplementary Fig. 3b–f). This evidence concerns the gene GPT and fatty liver disease.